Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
Open Access
- 5 May 2001
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 84 (9), 1146-1149
- https://doi.org/10.1054/bjoc.2000.1623
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastasesThe Lancet, 1998
- Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.Journal of Clinical Oncology, 1998
- Postsurgical adjuvant therapy for melanomaCancer, 1997
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Cutaneous malignant melanoma, Scotland, 1979-89The Lancet, 1992
- Interferons in the treatment of malignant melanoma. A review of recent trialsCancer, 1986